Efficacy of individualised starting dose (isd) and fixed starting dose (fsd) of niraparib per investigator assessment (ia) in newly diagnosed advanced ovarian cancer (oc) patients

Peen, U. (Ulla); Graybill, W. (Whitney); González-Martín, A. (Antonio); Omalley, D. (David); Baurain, J.F. (J. F.); Prendergast, E. (Emily); Follana, P. (Philippe); Braicu, E.I. (Elena Ioana); Gupta, D. (Dyvia); Monk, B.J. (Bradley J.)

Keywords:

Niraparib
Polymerase inhibitor
Maintenance treatment
Platinumbased chemotherapy

Issue Date:

2020

Publisher:

BMJ

ISSN:

1048-891X

Note:

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, an indication of whether changes were made, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

Citation:

Peen, U. (Ulla); Graybill, W. (Whitney); González-Martín, A. (Antonio); et al. "Efficacy of individualised starting dose (isd) and fixed starting dose (fsd) of niraparib per investigator assessment (ia) in newly diagnosed advanced ovarian cancer (oc) patients". International journal of gynecological cancer. 30 (Suppl 4), 2020, A1 - A142

Abstract

Niraparib is a poly(ADP-ribose) polymerase inhibitor approved for maintenance treatment of patients with newly diagnosed or recurrent OC that responded to platinumbased chemotherapy and treatment in heavily-pretreated recurrent OC. Here we report efficacy in patients receiving the FSD and ISD in the PRIMA/ENGOT-OV26/GOG-3012 trial (NCT02655016).

URI:

https://hdl.handle.net/10171/67945

DOI:

10.1136/ijgc-2020-ESGO.154

Appears in Collections:

DA - CUN - Oncología médica - Artículos de revista

Files in This Item: